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Several challenges needs to addressed before a gene 
expression profile can be approved as a predictive biomarker 
by regulatory bodies like the European Medicines Agency 
(EMA) and the US Food and Drug Administration (FDA). In an 
ongoing trial, EORTC-1219 (ClinicalTrials.gov ID: 
NCT01880359), a 15-gene hypoxia profile (1,2) is being tested 
prospectively. One of the primary aims of the study is to 
provide data for regulatory approval of the gene profile as an 
accompanying biomarker for the use of the hypoxia modifier 
Nimorazole. 
The development and ongoing validation of this 15-gene 
profile will be used as a general example of the challenges 
for implementing gene expression profiles in PRO. Different 
strategies for identification of relevant gene expression 
profiles will be discussed together with the challenges of 
validating the predictive value of a gene expression profile. 
The requirements for a quick and robust test for the gene 
expression profile working on simple routine FFPE (formalin-
fixed, paraffin-embedded) sections will also be discussed. 
Finally, some of the regulatory and patent issues related to 
gene expression profiles will be commented upon. 
1. Toustrup et al. Cancer Res. 71(17):5923-31, 2011. 
2. Toustrup et al. Radiother Oncol 102(1):122-9, 2012. 
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A key challenge in radiotherapy is to maximise radiation 
doses to cancer while minimising damage to surrounding 
healthy tissues. As toxicity in a minority of patients limits the 
doses that can be safely given to the majority, there is 
interest in developing a test to measure an individual’s 
radiosensitivity before treatment and predict their likelihood 
of developing toxicity. A biomarker that predicts a cancer 
patient’s risk of toxicity could be used to personalise dose 
prescriptions or to offer alternative treatments. Many 
approaches have been studied to measure radiosensitivity. 
The development of omics technologies underpinned genome 
wide association studies (GWAS) attempting to identify 
genetic variants reported as single nucleotide polymorphisms 
(SNPs). The advantages of the approach include: a genetic 
test will be easier to implement clinically than a functional 
assay; a genetic test will not suffer from the poor 
reproducibility associated with some radiosensitivity testing 
methods; and SNPs are the most common type of genetic 
variation and so easiest to identify. Omics technologies offer 
promise, but to have an impact on radiotherapy practice 
research must identify biomarkers that replicate across 
cohorts. Robust replication needs big data, which is only 
possible with large collaborative efforts. The need for big 
data was addressed by establishing an international 
Radiogenomics Consortium. Achievements of the consortium 
include: pooling cohorts to increase statistical power and 
identify definitively whether individual SNPs are associated 
with risk of toxicity; producing guidelines to improve the 
reporting of radiogenomics studies; identifying approaches 
for analysing data from heterogeneous cohorts involving 
different toxicity reporting scales and treatment regimens; 
and establishing studies collecting standardised data to 
improve our ability to detect more SNPs. Work over the past 
three years showed it is possible to pool heterogeneous 
cohorts and has identified several SNPs associated with risk 
of toxicity. Large collaborative projects in the cancer pre-
disposition field involving analysis of ~100,000 participants 
shows that sufficient SNPs can be identified to generate a 
polygenic risk profile for clinical implementation. For 
example, men in the top 1% of the distribution of a 74-SNP 
polygenic risk score have a 4.7 fold increased risk of 
developing prostate cancer. Key challenges for the radiation 
oncology community are to collect the data in multiple 
cancers to identify enough SNPs to generate a polygenic risk 
profile and to increase understanding of the need for 
endpoint dependent versus independent profiles. 
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Personalized Radiation Oncology (PRO) integrating omics 
technology is a rapidly developing concept that will have an 
enormous impact on oncologic treatments and specifically 
radiation therapy in the near future. Tumor behaviour and 
outcomes related to oncologic treatments are related to 
several factors of which connections are nowdays poorly 
known. Different branches of medicine have developed their 
own lines of research which are sometimes difficult to be 
interpreted, difficult to be integrated with classical clinical 
factors and for these reasons, difficult to be applied in 
clinical practice. In clinical prediction and decision making 
process, results provided by omics are rarely used, whereas 
clinicians usually use clinical and imaging data for 
understanding tumor behaviour, predicting patients' 
outcomes and for choosing the the most suitable treatment. 
The clinical decision is usually based on general guidelines 
which extrapolate information from randomized clinical trial. 
Moreover independent factors derived from several RCT are 
used by the Radiation Oncologist to make his prevision on 
tumor behaviour and consequently to choose the „right 
treatment“ for a specific patient. Randomized clinical trials 
enclose patients with characteristics chosen beforehand and 
usually omics informations are rarely or never included. This 
lead to a potential missing of several information that could 
refine prediction and thus promote personalized treatments 
and to an erroneous outcomes prediction that can lead to un-
appropriate treatment decision for a specific patient. 
Integrative data analysis has the potential to correlate data 
of different origins (genetic, radiology, clinic...) with 
patient’s outcomes and to create a consistent dataset useful 
to obtain a trustful analysis for the Decision Support System. 
The DSS can easily be applied in clinical practice helping the 
Radiation Oncologist to utilize several information that 
otherwise would be excluded in the process of decision 
making. The possibility to predict the outcome for a certain 
patient in combination with a specific treatment with more 
accuracy, will lead to better identification of risk groups and 
thus better treatment decisions in individual patients, but it 
will also stimulate research focused on specific risk groups 
which try to find new treatment options or other 
combinations of treatment options for these subgroups. 
These treatments will be more personalized, which will not 
only save patients from unnecessary toxicity and 
inconvenience, but will also facilitate the choice of the most 
appropriate treatment . The resulting predictive models, 
based on patient features, enable a more patient specific 
selection from the treatment options menu and a possibility 
to share decisions with patients based on an objective 
evaluation of risks and benefits. Finally, considering the 
important role that predictive models could play in the 
clinical practice, clinicians must be aware of the limits of 
these prediction models. They need to be internally validated 
taking into account the quality of the collected data. An 
external validation of models is also essential to support 
general applicability of the prediction model. Therefore 
structural collaboration between different groups is crucial to 
generate enough anonymized large databases from patients 
included or not in clinical trials.  
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Purpose or Objective: To determine gene signatures which 
predict loco-regional control (LRC) and the secondary 
endpoints overall survival (OS) and freedom of distant 
metastases (FDM) of locally advanced head and neck 
squamous cell carcinoma (HNSCC) after postoperative 
radiochemotherapy. 
 
Material and Methods: A gene expression panel of 216 genes 
was composed including genes which are involved in 
proliferation, invasion and metastasis as well as in 
radio(chemo)resistance associated with tumour hypoxia, 
cancer stem cell markers, cisplatin-resistance and DNA 
repair. Gene expression analysis was performed using 
NanoString technology on a multicentre retrospective patient 
cohort of 196 patients with HNSCC who received 
postoperative radiochemotherapy. Gene signatures with a 
minimal number of contributing genes were extracted, which 
optimally predict for LRC and the secondary endpoints OS and 
FDM. For the construction of these minimal signatures, 
different statistical methods were compared, including Cox 
regression with forward variable selection, boosting methods 
and random forests. To assess the performance of the 
different gene signatures and statistical methods the 
concordance index (CI) was evaluated using 3-fold internal 
cross validation. 
 
Results: The resulting gene signatures mostly contained 
genes related to cellular proliferation, migration, invasion, 
and tumour hypoxia. For all endpoints and statistical methods 
a cross-validated CI>0.7 could be obtained, indicating a good 
performance of the models. Using the linear predictor  
 
 
 
as a risk variable allowed for splitting the patient cohort into 
groups of good and bad prognosis. The figure exemplarily 
shows Kaplan-Meier curves of the total patient cohort split by 
the median risk variable of the gene signatures determined 
by Cox regression with forward variable selection for all 
endpoints. The difference between the survival curves is 
highly significant (p<0.001). 
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Conclusion: We determined gene signatures for the 
prediction of LRC, OS and FDM in a cohort of 196 HNSCC 
patients after postoperative radiochemotherapy. The 
signatures showed a good prognostic value and were 
validated by internal cross validation. After validation with 
an external dataset and in a currently ongoing multicentre 
prospective trial within the study group, the gene signatures 
may help to further stratify patients for individualised 
treatment de-escalation or intensification strategies. 
 
Symposium: The tumour in 3D: the role of tumour 
microenvironment  
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Novel 3D cell culture models enable cell growth in a more 
physiological environment than conventional 2D cell cultures. 
Most importantly, cells need to be embedded in a 
composition of extracellular matrix proteins similarly present 
in situ to guarantee conservation of the phenotype. As shown 
by comparative analyses between 2D, 3D and tumor 
xenografts, various processes such as signal transduction and 
DNA repair share great similarity in 3D and in-vivo but not 2D. 
Based on our long-standing experience, a large variety of 
endpoints can be determined and many methods can be 
conducted in 3D matrix-based cell cultures. While this is 
sometimes not as easy as in 2D and also requires a bit more 
financial invest, the generated data reflect cell behavior in-
vivo and thus have a higher clinically relevance. Further, we 
are able to address specific tumor features in detail. For 
example, malignant tumors show great genetic/epigenetic 
and morphological/cell biological heterogeneity. Here, a 
prime example is the stiffness of a tumor. Although we know 
that the stiffness greatly varies in different parts of the 
tumor, the underlying mechanisms and prosurvival 
consequences on the genetic/epigenetic and 
morphological/cell biological level are far from being 
understood. 3D matrix-based cell cultures models can 
elegantly support our efforts to gain more knowledge in this 
field. Another important point is the sparing of animal 
experiments based on our broad knowledge that human 
(patho)physiology is significantly different from mice (or 
other species). Many decades of in-vivo research have 
demonstrated that only a negligible proportion of therapeutic 
approaches could be translated from rodents to humans. In 
conclusion, 3D cell cultures are powerful tools to generate 
more clinically relevant information. A broader 
implementation of this methodology is likely to underscore 
our efforts to better understand tumor and normal cell 
radiation responses and foster identification of most critical 
cancer targets. 
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The response of normal tissues to irradiation is mainly 
determined by the survival and regenerative potential of the 
tissue stem cells, and modulated by inflammatory processes, 
vasculature damage and altered neuronal innervation and 
fibrosis. Interestingly, transplantation of tissue specific stem 
cells has been shown to restores tissue homeostasis and 
prevent late radiation effects. Moreover, the sparing of 
localized stem cells was predicted to preserve salivary gland 
function in patients treated for head and neck cancer. 
Interestingly, mounting evidence indicates that cancer stem 
cells might contribute to the poor prospects. Recently, we 
and others have developed methods to culture patient 
specific organ and tumour stem cell containing organoids 
(tissue resembling structures). These organoids contain all 
the tissue/tumor lineages and the tissue/tumor stem cells, as 
indicated by their secondary organoids self-renewal potential 
and regeneration/regrowth potential and offer the 
opportunity to investigate tissue and patient specific 
assessment of the response of stem cells to (chemo-) 
radiotherapy. Stem cell survival curves and DNA DSB repair 
kinetics indicate that the response of organoids to different 
radiation qualities may differ from tissue to tissue, especially 
in the low dose regions typically delivered to the normal 
tissue outside the planning target volume. Therefore, 
organoids cultures could be used to investigate the 
mechanism of differences in response of normal and tumour 
stem cells to irradiation and exploit these for personalized 
optimisation of (chemo-) radiation treatment and prediction 
of treatment response. 
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